The Real Message Behind Commercial mRNA Products eBook
Read the article:
Read the eBook:
News|Articles|April 15, 2023
- The Real Message Behind Commercial mRNA Products, April 2023 eBook
- Volume 2023 eBook
- Issue 3
- Pages: 22–25
Stability in mRNA-LNP Formulations
Author(s)Cynthia A. Challener
Lipids aren’t the only important ingredients influencing stability and in vivo performance.
Advertisement
For messenger RNA (mRNA) therapeutics and vaccines formulated as lipid nanoparticles (LNPs), the excipients receiving the most attention are the encapsulating lipids. While these compounds are crucial to the stability and delivery of mRNA-LNPs, the non-lipid excipients also play crucial roles in the function of final drug products. They impact the morphology and stability of these delivery systems, which in turn affects in vivo performance and the overall usefulness of mRNA drugs developed using nanoparticle technology.
Read this
About the author
Cynthia A. Challener, PhD has been a freelance technical writer for over 20 years and contributes regularly to BioPharm International and Pharmaceutical Technology.
Article details
Pharmaceutical Technology
eBook: The Real Message Behind Commercial mRNA Products
April 2023
Pages: 22–25
Citation
When referring to this article, please cite it as Challener, C. A. Excipients Impact Stability in mRNA-LNP Formulations. Pharmaceutical Technology's The Real Message Behind Commercial mRNA Products eBook (April 2023).
Editor’s note: This article was originally published in Pharmaceutical Technology 2023 47 (3).
Articles in this issue
over 3 years ago
Nucleic Acid-based Therapeutics Are Stepping into the Spotlightover 3 years ago
Learning to Think at Lightspeedover 3 years ago
Managing mRNA Instabilityover 3 years ago
The Marriage of RNA and Mass Spectrometryover 3 years ago
Delivering on the Potential of mRNA TherapeuticsAdvertisement
Related to this article
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why AI Model Updates Need Change Control: AAPS PharmSci 360 2026
2
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
3
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
4
AI Formulation: Regulators Want Data
5